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Abstract
 
This report shows that cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) plays a key role
in T cell–mediated dominant immunologic self-tolerance. In vivo blockade of CTLA-4 for a
limited period in normal mice leads to spontaneous development of chronic organ-specific au-
toimmune diseases, which are immunopathologically similar to human counterparts. In normal
naive mice, CTLA-4 is constitutively expressed on CD25
 
1
 
CD4
 
1
 
 T cells, which constitute 5–10%
of peripheral CD4
 
1
 
 T cells. When the CD25
 
1
 
CD4
 
1
 
 T cells are stimulated via the T cell re-
ceptor in vitro, they potently suppress antigen-specific and polyclonal activation and prolifera-
tion of other T cells, including CTLA-4–deficient T cells, and blockade of CTLA-4 abrogates
the suppression. CD28-deficient CD25
 
1
 
CD4
 
1
 
 T cells can also suppress normal T cells, indi-
cating that CD28 is dispensable for activation of the regulatory T cells. Thus, the CD25
 
1
 
CD4
 
1
 
regulatory T cell population engaged in dominant self-tolerance may require CTLA-4 but not
CD28 as a costimulatory molecule for its functional activation. Furthermore, interference with
this role of CTLA-4 suffices to elicit autoimmune disease in otherwise normal animals, pre-
sumably through affecting CD25
 
1
 
CD4
 
1
 
 T cell–mediated control of self-reactive T cells. This
unique function of CTLA-4 could be exploited to potentiate T cell–mediated immunoregula-
tion, and thereby to induce immunologic tolerance or to control autoimmunity.
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Introduction
 
CTL-associated antigen 4 (CTLA-4 [CD152]) is a CD28
homologue expressed on activated T cells and, upon inter-
action with CD80 or CD86 on APCs, exerts a downregu-
latory or attenuating effect on T cell–mediated immune re-
sponses (1, 2). Accumulating evidence indicates that it also
plays an important role in immunologic self-tolerance in
the periphery. CTLA-4–deficient mice, for example, de-
velop a severe lymphoproliferative disorder and die from
autoimmune-like disease within 1 mo after birth (3, 4).
Administration of anti–CTLA-4 Ab exacerbated autoim-
mune responses in a murine model of multiple sclerosis or
insulin-dependent diabetes mellitus (IDDM [5–7]), en-
hanced tumor immunity (8), or prevented the induction of
immunologic tolerance to concurrently administered non–
self-antigens (9). However, it is uncertain whether these
findings can be explained by the current notion that
CTLA-4 transduces negative signals to activated effector T
cells (1, 2, 10). In this report, we show another possible
role of CTLA-4 in immunologic self-tolerance.
 
There is accumulating evidence that, in addition to clonal
deletion or anergy, T cell–mediated dominant control of
self-reactive T cells represents one mechanism for maintain-
ing immunologic self-tolerance (11). For example, removal
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of a subpopulation of CD4
 
1
 
 T cells leads to spontaneous
development of various T cell–mediated autoimmune dis-
eases (e.g., thyroiditis, gastritis, and insulin-dependent dia-
betes mellitus) in otherwise normal rodents, and reconstitu-
tion of the removed population prevents the autoimmune
development (12, 13). Elimination of CD25
 
1
 
CD4
 
1
 
 T cells
(which constitute 5–10% of peripheral CD4
 
1
 
 T cells in
normal naive mice), for example, elicits various autoim-
mune diseases in genetically susceptible strains of mice (14–
20). The elimination also evokes potent tumor immunity in
otherwise nonresponding animals (17). These
 
 
 
in vivo and in
vitro findings, especially similar effects of CTLA-4 blockade
and CD25
 
1
 
 T cell elimination on autoimmunity and tumor
immunity, have led us to examine possible involvement of
CTLA-4 in T cell–mediated immunoregulation.
Here, we demonstrate that CTLA-4 is indeed a key co-
stimulatory molecule for activating CD25
 
1
 
CD4
 
1
 
 regula-
tory T cells to exert suppression and thereby to control
self-reactive T cells, and that in vivo blockade of CTLA-4
expressed on the regulatory T cells suffices to break natural
self-tolerance and elicit pathological autoimmunity.
 
Materials and Methods
 
Mice.
 
8-wk-old BALB/c, BALB/c athymic nude, or C57BL/6
(B6) mice were purchased from SLC. DO11.10 transgenic mice
expressing transgenic TCR specific for an OVA peptide were the
gift of Dr. D.Y. Loh (Roche Japan, Kamakura, Japan). CTLA-4–
or CD28-deficient mice on the B6 background were described
previously (3, 21). All these mice were maintained in our animal
facility and cared for in accordance with the institutional guide-
lines for animal welfare.
 
In Vivo Injection of mAb.
 
The hybridoma cells secreting ham-
ster anti–CTLA-4 mAb (UC10-4F10-11) were a gift from Dr. J.
Bluestone (University of Chicago, Chicago, IL [22]). The Ab was
purified from ascites in SCID mice using protein A columns (22,
23). Rat anti-CD25 mAb (PC61) was purified from ascites in
SCID mice by 40% ammonium sulfate precipitation twice as de-
scribed previously (17).
 
Serologic Analysis.
 
For flow cytometric analysis, 10
 
6
 
 cells were
incubated with FITC- or PE-labeled or biotinylated mAbs, with
 
RPE–CyChrome 5–streptavidin (Dako) as the secondary reagent
for biotinylated Abs, and analyzed by flow cytometry (Epics-XL;
Beckman Coulter). FITC-labeled or biotinylated anti-CD25
mAb (7D4), FITC–anti-CD4 mAb (H129.19), PE-labeled anti–
CTLA-4 mAb (UC10-4F10-11), and anti-FcR mAb (2.4G2)
were purchased from BD PharMingen.
 
Cell Sorting.
 
Spleen and lymph node cell suspensions pre-
pared from 8-wk-old BALB/c, DO11.10, or CD28-deficient
mice or 2–3-wk-old CTLA-4–deficient mice were stained with
FITC–anti-CD25 mAb (7D4) and PE–anti-CD4 mAb (H129.19;
BD PharMingen) and sorted by a FACS
 
®
 
 (Epics-Elite; Beckman
Coulter), as described previously (18, 19). Purity of the CD25
 
1
 
or CD25
 
2
 
CD4
 
1
 
 population was 
 
.
 
90% and 
 
z
 
99%, respectively.
 
In Vitro Proliferation Assay.
 
Lymph node and spleen T cells
(2.0–2.5 
 
3
 
 10
 
4
 
), sorted as described above, and red blood cell–
lysed, x-irradiated (20 Gy) BALB/c spleen cells (5 
 
3
 
 10
 
4
 
) as APCs
were cultured for 3 d in 96-well round-bottomed plates (Costar)
in RPMI 1640 medium supplemented with 10% FCS (GIBCO
BRL), penicillin (100 U/ml), streptomycin (100 
 
m
 
g/ml), and 50
 
m
 
M 2-ME. Anti–CD3 mAb (145-2C11; Cedarlane Laboratories)
at a final concentration of 10 
 
m
 
g/ml or Con A at 1 
 
m
 
g/ml were
added to the culture for stimulation (18, 19). Incorporation of
 
3
 
H-TdR (1 
 
m
 
Ci/well; Dupont) by proliferating lymphocytes
during the last 6 h of the culture was measured (18, 19). Fab frag-
ments of anti–CTLA-4 mAb or normal hamster IgG (Cortex
Biochem, Inc.) were prepared by digesting these Abs with immo-
bilized papain (Pierce Chemical Co.) according to the manufac-
turer’s instruction.
 
Histology and Serology.
 
Stomachs and other organs were fixed
with 10% formalin and processed for hematoxylin and eosin
staining. Serum titers of autoantibodies specific for the gastric pa-
rietal cells were assayed by ELISA (14, 15). Gastritis was graded
0–2
 
1 
 
depending on macroscopic and histological severity, as de-
scribed previously (12, 14, 15).
 
Results and Discussion
 
Constitutive Expression of CTLA-4 on CD25
 
1
 
CD4
 
1
 
 T
Cells in Normal Naive Mice.
 
CTLA-4 is supposed to be
expressed on T cells only after activation (1, 2). However,
in the peripheral lymphoid organs of normal naive mice,
flow cytometric analysis of cell surface as well as cytoplas-
Figure 1. Constitutive expression of
CTLA-4 on CD251CD41 T cells in normal
naive mice. Lymph node and spleen cell sus-
pensions prepared from a 2-mo-old BALB/c
mouse were stained with FITC–anti-CD4
Ab and biotinylated anti-CD25 Ab with
RPE-CyChrome 5–conjugated streptavidin
as the secondary reagent. Cells enclosed
with rectangles were sorted as CD251 or
CD25241 T cells. The sorted cells were
stained for 2 h at 378C with PE-conjugated
anti–CTLA-4 Ab or PE-conjugated anti–
human CD4 Ab as a staining control, and
are shown as histograms (solid lines or
shaded areas, respectively; the abscissa shows
the staining intensity on a logarithmic scale
and the ordinate shows the number of cells
on an arbitrary scale) (reference 28). The
sorted cells were also cultured with Con A (1 mg/ml) at 378C for 24 h and incubated for the last 2 h with PE–anti–CTLA-4 Ab. CD28 expression on
CD251 or CD25241 T cells is shown as histograms by staining the cells with PE–anti-CD28 Ab. A representative result of five independent experiments
is shown. Stim., stimulation. 
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mic expression of CTLA-4 revealed that the molecule was
constitutively expressed on/in CD25
 
1
 
CD4
 
1
 
 T cells but
not on/in CD25
 
2
 
CD4
 
1
 
 T cells (or CD8
 
1
 
 T cells; data not
shown) whether the mice were raised in a specific patho-
gen-free condition or not (Fig. 1). Both populations ex-
pressed high levels of CTLA-4 upon in vitro T cell stimu-
lation (for example, with Con A). The two populations
showed no difference in their expression levels of CD28,
which appears to be constitutively expressed on all murine
T cells (24).
 
Induction of Autoimmune Disease in Normal Mice by Anti–
CTLA-4 Ab Treatment.
 
To determine the role of CTLA-4
expressed on CD25
 
1
 
CD4
 
1
 
 T cells in self-tolerance and
autoimmunity, we administered purified anti–CTLA-4
mAb (0.8 or 0.1 mg), anti-CD25 mAb (1 mg), or the mix-
ture of anti–CTLA-4 mAb (0.1 mg) and anti-CD25 mAb
(1 mg) once a week three times to normal BALB/c mice
from the age of 10 d, and examined the mice at 3 mo of
age (17, 25; Fig. 2). All the mice treated with high doses
(0.8 mg/injection) of anti–CTLA-4 mAb spontaneously
developed histologically and serologically evident autoim-
mune gastritis and some other autoimmune diseases (i.e.,
oophoritis or mild sialoadenitis, in one mouse each) (12,
14, 15; Fig. 2, A–C). Low doses of anti–CTLA-4 mAb or
anti-CD25 mAb alone induced only low titers of autoanti-
body without histological evidence of autoimmune disease,
whereas treatment with the mixture of the two mAbs pro-
duced autoimmune gastritis in the majority (
 
z
 
85%) of
mice.
Administration of anti-CTLA-4 mAb did not signifi-
cantly alter the number of CD25
 
1
 
CD4
 
1
 
 T cells or the ra-
tio of CD25
 
1
 
 T cells among CD4
 
1
 
 T cells, whereas ad-
ministration of anti-CD25 mAb or the mixed mAbs
reduced CD25
 
1
 
CD4
 
1
 
 T cells to 10–30% of the controls
Figure 2. Induction of autoimmune disease in BALB/c
mice by administration of anti–CTLA-4 Ab with or
without anti-CD25 Ab. (A) BALB/c mice were injected
intraperitoneally with indicated doses of purified anti–
CTLA-4 mAb, anti-CD25 mAb, a mixture of the two
mAbs, or control rat Ig once a week three times from the
age of 10 d, and were examined at 3 mo of age for histo-
logical and/or serological development of autoimmune
disease. The gastric lesion was histologically graded as
macroscopically and histologically evident grade-2 gastri-
tis (black circle), histologically evident grade-1 gastritis
(gray circle), or intact gastric mucosa (white circle; for
detailed grading, see references 12, 14, 15). Titers of anti-
parietal cell autoantibodies were assessed by ELISA. The
gastric mucosa of a grade-2 gastritis in a mouse treated with anti–CTLA-4 mAb is shown in B, and the intact gastric mucosa of a mouse treated with rat Ig is
shown in C. Samples were stained with hematoxylin and eosin (original magnification: 325). (D) Composition of T cell subpopulations defined by the ex-
pression of CD4 and CD25 7 d after the last Ab treatment. Lymph node cells were stained with PE–anti-CD4 mAb and FITC–anti-CD25 mAb, 7D4, an-
other anti-CD25 mAb with different epitope specificity, as described previously (reference 18). A representative staining of three independent experiments is
shown. (E) Spleen cells (5 3 107) from anti–CTLA-4 mAb– or mixed mAb–treated mice with gastritis or from rat Ig–treated mice were transferred intrave-
nously to BALB/c athymic nude mice, which were histologically and serologically examined 2 mo later. Black circle, macroscopically and histologically evi-
dent grade-2 gastritis; gray circle, histologically evident grade-1 gastritis; white circle, intact gastric mucosa. A representative result of more than three inde-
pendent experiments is shown. The means of duplicate cultures are shown, and the SEM was within 10% of the mean for each experiment. 
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(Fig. 2 D). For example, 1 wk after the last treatment, per-
centages of CD25
 
1
 
 cells among the CD4
 
1
 
 cells in the
lymph nodes were 7.2
 
 6 
 
0.3% in the control mice, 10.1
 
 6
 
0.30% and 9.6
 
 6 
 
0.26% in the high- or low-dose anti–
CTLA-4 mAb–treated mice, respectively, 0.93
 
 6 
 
0.15% in
the anti–CD25 mAb–treated mice, and 2.1
 
 6 
 
0.1% in the
mixed mAb–treated mice (
 
n
 
 5 
 
3 for each).
The affected gastric mucosa was characterized by loss
and damage of the parietal cells and the chief cells, com-
pensatory hyperplasia of mucous-secreting cells, and a
massive infiltration of mononuclear cells (Fig. 2, B and C).
The lesion was immunopathologically similar to human
autoimmune gastritis with pernicious anemia (26). Fur-
thermore, the gastritis thus induced could be adoptively
transferred to naive BALB/c athymic nude mice by spleen
cells from gastritis-bearing BALB/c mice, indicating that
the lesion was a result of a
 
 
 
bona fide autoimmune disease
(Fig. 2 E).
Thus, autoimmune diseases similar to those produced by
elimination of CD25
 
1
 
CD4
 
1
 
 T cells could be elicited in
normal mice by blockade of CTLA-4 with high-dose anti–
CTLA-4 Ab, or reduction of CD25
 
1
 
CD4
 
1
 
 T cells accom-
panied by CTLA-4 blockade on the residual T cells with
low-dose anti–CTLA-4 Ab (14, 15). In the latter treatment,
it is plausible that reduction of CD25
 
1
 
CD4
 
1
 
 T cells might
have partially triggered the activation of autoimmune effec-
tor T cells, which might then be further activated by the
blockade of CTLA-4 expressed on them. Nevertheless,
successful autoimmune induction by CTLA-4 blockade
alone without reduction of CD25
 
1
 
CD4
 
1
 
 T cells (Fig. 2
D), together with the constitutive expression of CTLA-4
on normal CD25
 
1
 
CD4
 
1
 
 T cells (Fig. 1), indicates that the
blockade of CTLA-4 on the CD25
 
1
 
CD4
 
1
 
 T cells is most
likely the triggering mechanism of this autoimmunity.
Role of CTLA-4 in CD251CD41 T Cell–mediated Sup-
pression In Vitro. CD251CD41 T cells present in normal
naive mice exhibited no proliferative response to TCR
stimulation, whereas, upon TCR stimulation, they po-
tently suppressed the activation and proliferation of other T
cells, as reported previously (18–20, 27; Fig. 3). To exam-
ine the possible role of CTLA-4 in this natural anergy and
suppression, we added anti–CTLA-4 Ab, its Fab fragments,
or control hamster Ab to 3-d cultures of CD251CD41 T
cells or CD252CD41 T cells (purified as shown in Fig. 1),
or a mixture of an equal number of the two populations,
and stimulated the cultures with Con A (Fig. 3 A) or solu-
ble anti-CD3 mAb (Fig. 3 B) along with APCs. Anti-
FcgII/III receptor (FcR [CD16/CD32]) mAb was also
added to some cultures to inhibit anti–CTLA-4 mAbs from
attaching to FcRs on APCs, thereby preventing the Abs
Figure 3.  Key role of CTLA-4 expressed
on CD251CD41 regulatory T cells in
downregulating the activation and prolifera-
tion of other T cells. (A) Anti–CTLA-4
mAb (100 mg/ml) or control hamster Ab
with or without anti-FcR mAb (10 mg/ml)
or Fab–anti-CTLA-4 mAb (100 mg/ml)
was added to the culture of CD251 or
CD252CD41 T cells purified from BALB/c
spleen and lymph node cells (as shown in
Fig. 1), or these two populations were
mixed at a 1:1 ratio. The culture was stimu-
lated for 3 d with Con A (1 mg/ml) along
with irradiated BALB/c spleen cells as
APCs. Incorporation of 3H-TdR during the
last 6 h of the culture is shown as the degree
of proliferation. Background counts in the
wells with APCs alone were always ,1,500
cpm in these experiments and those below.
a, anti-. (B) CD251 or CD252CD41 T
cells or a 1:1 mixture of the two populations
were stimulated with anti-CD3 mAb (10
mg/ml) in the presence of Fab–anti–CTLA-4
mAb at various concentrations (black sym-
bols) or control Fab–hamster IgG at 300
mg/ml (white symbols). (C) CD251 or
CD252CD41 T cells or two populations
mixed at an equal ratio, purified from the
spleens of DO11.10 transgenic mice, were
cultured for 3 d with 0.1 mM OVA-P(323–
339) in the presence of Fab–anti–CTLA-4
mAb or control Fab–hamster IgG at 100 mg/ml. a, anti-. (D) CD252CD41 T cells prepared from 3-wk-old CTLA-4–deficient (CTLA-42/2) B6 mice or a
1:1 mixture of these cells with CD251CD41 T cells from 2-mo-old normal B6 mice was stimulated with anti-CD3 mAb for 3 d in the presence of Fab–
anti–CTLA-4 mAb at indicated concentrations. The counts of CTLA-4–deficient CD252CD41 T cells cultured without stimulation were background lev-
els (i.e., ,2,000 cpm). a, anti-. (E) CD251CD41 T cells prepared from CD28-deficient (CD282/2) B6 mice or normal B6 mice were mixed with an equal
number of CD252CD41 T cells from normal B6 mice and stimulated with anti-CD3 mAb for 3 d. A representative result of more than three independent
experiments is shown. The means of duplicate cultures are shown, and the SEM was always with 10% of the mean for each experiment.307 Takahashi et al. Brief Definitive Report
from cross-linking CTLA-4 and transducing signals (22,
23). In these experiments, intact anti–CTLA-4 mAb, espe-
cially in the presence of anti-FcR mAb, significantly neu-
tralized CD251CD41 T cell–mediated suppression of the
activation and proliferation of CD252CD41 T cells (Fig. 3
A). Although others reported no significant effect of anti–
CTLA-4 mAb in a similar cell culture system (20), the dis-
crepancy could be attributed to the concentration of anti–
CTLA-4 mAb in the culture; i.e., with a high dose (100
mg/ml) of anti–CTLA-4 mAb, as shown here, the majority
of CTLA-4 molecules could be blocked rather than cross-
linked by the Ab attached to FcR on APCs. This blocking
effect was further supported by the result that Fab–anti–
CTLA-4 mAb, which is presumably able to block but un-
able to cross-link CTLA-4 (22, 23), more efficiently abro-
gated the suppression in a dose-dependent fashion (Fig. 3,
A and B). In addition to these polyclonal T cell activations,
the Fab fragments also neutralized CD251CD41 T cell–
mediated control of antigen-specific activation and prolif-
eration of OVA-specific T cells from DO11.10 transgenic
mice (18, 19; Fig. 3 C). On the other hand, intact or Fab–
anti–CTLA-4 mAb did not significantly affect the re-
sponses of CD252CD41 T cells or break the anergic state
of CD251CD41 T cells (Fig. 3, A–C).
To determine more definitely the role of CTLA-4 on
CD251CD41 T cells, we used CTLA-4–deficient mice.
CD251CD41 T cells from normal mice efficiently sup-
pressed CD252CD41 T cells from CTLA-4–deficient
mice, and Fab–anti-CTLA-4 mAb abrogated this suppres-
sion in a dose-dependent fashion (Fig. 3 D). In the recipro-
cal combination, CTLA-4–deficient CD251CD41 T cells
also exhibited weak suppressive activity (z50% in percent-
age suppression compared with .95% by normal CD251
CD41 T cells at 1:1 mixing with CD252CD41 T cells).
The CD251 T cells constituted up to 30% of CD41 T cells
in the enlarged spleens of CTLA-4–deficient mice and ap-
peared to be different from normal CD251CD41 T cells in
including a large number of abnormally activated T cells
(3). It remains to be determined whether this weak suppres-
sive activity could be peculiar to CTLA-4–deficient
CD251CD41 T cells (e.g., because of compensatory activa-
tion of other genes encoding molecules concerned with the
suppression). Indeed, blockade of certain other cell surface
molecules could abrogate the suppressive activity of CTLA-
4–deficient as well as normal CD251CD41 T cells (our un-
published results). Despite this possibility, the results in Fig.
3, A–D, when taken together, indicate that CTLA-4 ex-
pressed on CD251CD41 regulatory T cells is critically in-
volved in this in vitro T cell–mediated immunoregulation.
Activation of T cells usually requires a costimulatory sig-
nal through CD28 in addition to the TCR signal (24).
However, CD251CD41 T cells from CD28-deficient
mice exhibited a potent suppressive activity (Fig. 3 E). This
indicates that CD28 on CD251CD41 T cells (Fig. 1) is dis-
pensable for the CD251CD41 T cell–mediated suppres-
sion, even if CD28 deficiency might affect the develop-
ment of regulatory T cells (e.g., the number of CD251
CD41 T cells in CD28-deficient B6 mice reduced to
z20% of normal B6 mice; our unpublished data) or their
level of CTLA-4 expression (28, 29). On the other hand,
we have shown previously that ligation of the CD28 mole-
cule with anti-CD28 Ab, in conjunction with TCR stimu-
lation, can break the naturally anergic state of CD251
CD41 T cells and simultaneously abolish their suppressive
activity (18, 19). These findings collectively imply unique
roles for CTLA-4 and CD28 in CD251CD41 regulatory T
cells; i.e., costimulation via CTLA-4 may activate the regu-
latory T cells to exert suppression, whereas costimulation
via CD28 may attenuate their suppressive activity. The bal-
ance between the two signals in a particular CD251CD41
regulatory T cell may be critical in determining its activa-
tion threshold and/or its suppressive activity. Furthermore,
the balance between regulatory T cells activated through
CTLA-4 and effector T cells activated through CD28 may
contribute to determining the threshold or the magnitude
of a particular immune response.
It remains to be determined how CD251CD41 regula-
tory T cells suppressively control other T cells upon stimu-
lation via CTLA-4 and TCR. Although TGF-b possibly
secreted by TCR- and CTLA-4–stimulated T cells may
contribute to attenuating activated T cells, as shown by
others (30), anergic/suppressive CD251CD41 T cells stim-
ulated via CTLA-4 and TCR did not secrete detectable
amounts of TGF-b, and the suppression was not abrogated
by adding neutralizing anti–TGF-b Ab to the culture (18,
20; our unpublished data). As a possible mechanism of the
suppression, CD251CD41 T cells stimulated via CTLA-4
and TCR may physically interfere with the interaction of
other T cells with APCs by competing for the costimula-
tory molecules on APCs, as they are predominantly ex-
pressing CTLA-4 (which has a higher affinity for CD80/
CD86 than CD28 [22]) and various adhesion molecules
(such as intercellular adhesion molecule [ICAM]-1, LFA-1,
and CD2) at high levels (18–20). Alternatively, the signals
via TCR and CTLA-4 may activate CD251CD41 T cells
to deliver to other T cells a negative signal for activation
and proliferation. These possibilities are currently under in-
vestigation.
There are accumulating demonstrations that CTLA-4
deficiency or blockade induces or exacerbates autoimmu-
nity, enhances tumor immunity, or prevents induction of
immunologic tolerance (4–9). These effects of CTLA-4 de-
ficiency or blockade have been largely explained as a hin-
drance of CTLA-4–transduced negative signals to activated
T cells mediating immune responses (1, 2). However, our
present in vivo and in vitro results indicate that the effects
can also be attributed, at least in part, to the blockade of
CTLA-4 molecules expressed on CD251CD41 regulatory
T cells and consequent interference with T cell–mediated
immunoregulation. CTLA-4 also appears to play a similar
role in the function of regulatory T cells that control in-
flammatory bowel disease (31). Exploitation of this unique
role of CTLA-4 in immunologic self-tolerance would help
to develop novel strategies for treating or preventing au-
toimmune disease, enhancing immunity to autologous tu-
mor cells, or inducing tolerance to allotransplants.308 CTLA-4 in CD251CD41 T Cell–mediated Immunoregulation
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